Active Biotech AB Interim Report January-June 2008

"Enrolment for another clinical Phase III study for laquinimod started during the period and complete Phase II data was published in the respected medical journal The Lancet. The planned interim analysis from the first part of the Phase II/III trial for the ANYARA cancer project presented positive data and the pivotal Phase III study commenced in May. We now have two Phase III projects and three clinical Phase II projects. Consequently, we have further strengthened Active Biotech's position as a company with a balanced and mature project portfolio."

 

For further information, please contact:

Sven Andréasson
President & CEO
Tel: +46 (0)46-19 20 49

 

Göran Forsberg                                    

VP Communication & Business Development                      

Tel: +46 (0)46-19 11 54        

 

Hans Kolam                                                                          Active Biotech AB

CFO                                                                                        (Corp. Reg. No. 556223-9227)

Tel +46 (0)46-19 20 44                                                          PO Box 724, SE-220 07 Lund

                                                                                               Tel +46 (0)46-19 20 00

                                                                                               Fax +46 (0)46-19 20 50

This report is also available at www.activebiotech.com